Douglas T. Sheehy Sells 7,460 Shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Stock
Aimmune Therapeutics, Inc. (NASDAQ:AIMT) insider Douglas T. Sheehy sold 7,460 shares of Aimmune Therapeutics stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $21.66, for a total value of $161,583.60. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) opened at 21.76 on Friday. The stock’s market cap is $1.10 billion. Aimmune Therapeutics, Inc. has a 52-week low of $11.40 and a 52-week high of $27.31. The company’s 50-day moving average price is $19.66 and its 200-day moving average price is $19.92.
Aimmune Therapeutics (NASDAQ:AIMT) last announced its earnings results on Monday, May 8th. The biotechnology company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.05. Analysts expect that Aimmune Therapeutics, Inc. will post ($2.66) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Douglas T. Sheehy Sells 7,460 Shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Stock” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/07/23/douglas-t-sheehy-sells-7460-shares-of-aimmune-therapeutics-inc-nasdaqaimt-stock.html.
A number of analysts recently commented on AIMT shares. Zacks Investment Research cut Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. ValuEngine cut Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 27th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Aimmune Therapeutics has an average rating of “Buy” and an average price target of $33.00.
A number of large investors have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Aimmune Therapeutics by 454.1% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,979 shares of the biotechnology company’s stock valued at $130,000 after buying an additional 4,900 shares in the last quarter. Daiwa SB Investments Ltd. acquired a new stake in shares of Aimmune Therapeutics during the first quarter valued at about $132,000. American International Group Inc. increased its stake in shares of Aimmune Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 16,184 shares of the biotechnology company’s stock valued at $352,000 after buying an additional 1,070 shares in the last quarter. Nationwide Fund Advisors increased its stake in shares of Aimmune Therapeutics by 23.7% in the first quarter. Nationwide Fund Advisors now owns 20,095 shares of the biotechnology company’s stock valued at $437,000 after buying an additional 3,851 shares in the last quarter. Finally, Franklin Street Advisors Inc. NC acquired a new stake in shares of Aimmune Therapeutics during the first quarter valued at about $450,000. 69.64% of the stock is owned by hedge funds and other institutional investors.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Stock Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related stocks with our FREE daily email newsletter.